What is the price-to-earnings ratio of Innoviva?
The price-earnings ratio of Innoviva is currently 4.
Innoviva P/S 2024
Innoviva P/S
4
Ticker
INVA
ISIN
US45781M1018
WKN
A2AC9U
As of Sep 16, 2024, Innoviva's P/S ratio stood at 4, a 8.99% change from the 3.67 P/S ratio recorded in the previous year.
The Innoviva P/S history
Innoviva Aktienanalyse
What does Innoviva do?
Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Innoviva's P/S Ratio
Innoviva's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Innoviva's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Innoviva's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Innoviva’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Innoviva stock
How has the price-earnings ratio of Innoviva changed compared to last year?
The price-to-earnings ratio of Innoviva has increased by 8.99% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Innoviva high compared to other companies?
Yes, the price-to-earnings ratio of Innoviva is high compared to other companies.
How does an increase in the price-earnings ratio of Innoviva affect the company?
An increase in the price-earnings ratio of Innoviva would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Innoviva affect the company?
A decrease in the price-earnings ratio of Innoviva would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Innoviva?
Some factors that influence the price-earnings ratio of Innoviva are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Innoviva pay?
Over the past 12 months, Innoviva paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 3.79 %. For the coming 12 months, Innoviva is expected to pay a dividend of 0 USD.
What is the dividend yield of Innoviva?
The current dividend yield of Innoviva is 3.79 %.
When does Innoviva pay dividends?
Innoviva pays a quarterly dividend. This is distributed in the months of December, April, July, October.
How secure is the dividend of Innoviva?
Innoviva paid dividends every year for the past 0 years.
What is the dividend of Innoviva?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Innoviva located?
Innoviva is assigned to the 'Health' sector.
Wann musste ich die Aktien von Innoviva kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Innoviva from 9/30/2015 amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2015.
When did Innoviva pay the last dividend?
The last dividend was paid out on 9/30/2015.
What was the dividend of Innoviva in the year 2023?
In the year 2023, Innoviva distributed 0 USD as dividends.
In which currency does Innoviva pay out the dividend?
The dividends of Innoviva are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Innoviva stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Innoviva
Our stock analysis for Innoviva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innoviva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
